In trading on Friday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 0.7% on the day. Components of that ETF showing particular strength include shares of Alnylam Pharmaceuticals ...

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an ...

RBC Capital initiated coverage of Ascendis Pharma (ASND) with an Outperform rating and $205 price target. The stock has outperformed the ...

The XBI fell more than 4% yesterday. The closely tracked index of biotech stocks is now down 13% since the announcement of President Trump’s tariff policy. It’s down 22% for the year.

Biotech investors are reeling after the sudden departure of Peter Marks, a pivotal figure in the U.S. Food and Drug Administration. Marks, who played a crucial role in Operation Warp Speed and ...

Stocks climbed on Wednesday in yet another volatile session as Wall Street readied for the expected rollout of President Donald Trump's tariffs. Shares of Tesla climbed 5.3%, rising on news that ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...

In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its ...